Multifactor predictive model in patients with myocardial infarction based on modern biomarkers

Хамитова, А. Ф.; Лакман, И. А.; Akhmetvaleev, R.R.; Тулбаев, Э. Л.; Gareeva, Diana; Загидуллин, Ш. З.; Загидуллин, Н. Ш.

doi:10.18087/cardio.2020.3.2593

Cited by 6 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the level of PTX3 detected at 1 month can still predict the composite cardiovascular endpoint (cardiovascular death, myocardial infarction or stroke). Khamitova et al 21 conducted a 1-year follow-up of 180 patients with myocardial infarction. The results showed that the risk assessment model established by PTX3 combined with NT-proBNP and soluble ST2 level could predict the risk of 1-year composite endpoint events (myocardial infarction, acute cerebrovascular disease, hospitalization for cardiovascular disease and cardiovascular death).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Pentraxin-3 Change After Primary Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction

Li¹,

Liu²,

Wang³

et al. 2023

JIR

View full text Add to dashboard Cite

Purpose So far, ST-segment elevation myocardial infarction (STEMI) is still the main cause of morbidity and mortality of cardiovascular diseases worldwide. Recent studies showed that pentraxin-3 (PTX3) was related to the early diagnosis and prognosis of coronary heart disease. This study aimed to investigate the dynamical change of PTX3 after primary percutaneous coronary intervention (pPCI) in STEMI patients and its prognostic value. Patients and methods In this prospective cohort study, a total of 350 patients were enrolled. The plasma level of PTX3 was measured at admission, 24-hour and 5-day after pPCI. The primary endpoint was the incidence of major adverse cardiac cerebral events (MACCEs) during 1-year follow-up. Results Compared with the admission, PTX3 levels were significantly increased at 24 hours, and decreased at 5 days after pPCI in the whole cohort. PTX3 levels at these three time points were not significantly different between the patients with and without MACCEs. Notably, the change in PTX3 from admission to post-pPCI 24-hour (ΔPTX3) was higher in patients with MACCEs (112.83 vs 17.94 ng/dl, P = 0.001). The ROC curves showed that the cut-off value was 29.22 ng/dl and the area under curves was 0.622 (95% CI: 0.554–0.690, p = 0.001). Multivariable cox regression models revealed that the high ΔPTX3 group was an independent predictor of MACCEs (adjusted HR = 2.010, 95% CI = 1.280–3.186, p = 0.003). The higher ΔPTX3 group had significantly higher incidences of revascularization (HR = 2.094, 95% CI: 1.056–4.150, p = 0.034) and composite MACCEs (HR = 2.219, 95% CI: 1.425–3.454, p < 0.001). However, the change of PTX3 level from admission to post-pPCI 5-day had no independently predictive value. Conclusion The higher increase of PTX3 level 24-hour after pPCI appeared to have a potential value in independently predicting the incidence of 1-year MACCEs in STEMI patients, especially for coronary revascularization.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Pentraxin-3 Change After Primary Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction

Li¹,

Liu²,

Wang³

et al. 2023

JIR

View full text Add to dashboard Cite

show abstract

“…In addition, it always leads to the increase of fibrinogen and induces a hypercoagulable state of blood vessels; moreover, its interaction with inflammatory reaction may cause unstable atherosclerotic plaque, thereby resulting in the occurrence of ACS; therefore, PTX-3 is considered to be an important predictor of ACS (29). There is a study that specifically revealed that the inclusion of PTX-3 improved the predictive model of cardiovascular complications in patients with myocardial infarction (30).…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value and prognostic significance of CTRP9 combined with pentraxin‑3 in acute coronary syndrome

et al. 2021

View full text Add to dashboard Cite

The present study aimed to explore the diagnostic value and prognostic significance of C1q/tumor necrosis factor-related protein 9 (CTRP9) combined with pentraxin-3 (PTX-3) in acute coronary syndrome (ACS). A total of 137 patients with coronary heart disease and chest pain were included. Among them, seventy-nine patients with ACS were allocated into a study group and fifty-eight patients with non-cardiac chest pain (NCCP) were allocated into a control group. The serum CTRP9, PTX-3 levels were quantified by ELISA, and their correlation with other ACS-related indexes, diagnostic value for ACS and predictive significance for poor prognosis were analyzed. In addition, the risk factors of the poor prognosis of ACS patients were studied. CTRP9 was lowly expressed and PTX-3 was highly expressed in the serum of ACS patients. CTRP9 was negatively correlated with cardiac troponin I (cTnI), creatine kinase-MB (CK-MB) and high-sensitivity C-reactive protein (hs-CRP) (P<0.05), while PTX-3 was positively correlated with them (P<0.05). Combined detection of CTRP9 and PTX-3 was of high value in the diagnosis and prognosis of ACS patients. In addition, CTRP9 and PTX-3 were independent risk factors for the poor prognosis of ACS. Patients with ACS had lower CTRP9 expression and higher PTX-3 expression than those without ACS. Moreover, the combined detection of CTRP9 and PTX-3 can better evaluate the diagnosis and prognosis of ACS patients.

show abstract

“…BNP is one of the most common CHF indicators [12,18]. According to some researches [19], such biomarkers as N-terminal pro-brain natriuretic peptide (NT-proBNP), pentraxin-related protein (PTX-3) and, to a lesser extent, stimulating growth factor 2 (ST2), have demonstrated their prognostic significance in diagnosis of cardiovascular complications with a sensitivity of 78.79% and a specificity of 86.67% (area under the curve, AUC 0.73). The current study has also established the role of BNP in long-term prognosis in STEMI patients, but this parameter has not been included in the multivariate model.…”

Section: Discussionmentioning

confidence: 99%

A Multivariate Model to Predict Chronic Heart Failure after Acute ST-Segment Elevation Myocardial Infarction: Preliminary Study

et al. 2021

View full text Add to dashboard Cite

A multivariate model for predicting the risk of decompensated chronic heart failure (CHF) within 48 weeks after ST-segment elevation myocardial infarction (STEMI) has been developed and tested. Methods. The study included 173 patients with acute STEMI aged 51.4 (95% confidence interval (CI): 42–61) years. Two-dimensional (2D) speckle-tracking echocardiography (STE) has been performed on the 7th–9th days, and at the 12th, 24th, and 48th weeks after the index event with the analysis of volumetric parameters and values for global longitudinal strain (GLS), global circumferential strain (GCS), and global radial strain (GRS). A 24-h ECG monitoring (24 h ECG) of the electrocardiogram (ECG) to assess heart rate turbulence (HRT) has been performed on the 7th–9th days of STEMI. The study involved two stages of implementation. At the first stage, a multivariate model to assess the risk of CHF progression within 48 weeks after STEMI has been built on the basis of examination and follow-up data for 113 patients (group M). At the second stage, the performance of the model has been assessed based on a 48-week follow-up of 60 patients (group T). Results. A multivariate regression model for CHF progression in STEMI patients has been created based on the results of the first stage. It included the following parameters: HRT, left ventricular (LV) end-systolic dimension (ESD), and GLS. The contribution of each factor for the relative risk (RR) of decompensated CHF has been found: 3.92 (95% CI: 1.66–9.25) (p = 0.0018) for HRT; 1.04 (95% CI: 1.015–1.07) (p = 0.0027) for ESD; 0.9 (95% CI: 0.815–0.98) (p = 0.028) for GLS. The diagnostic efficiency of the proposed model has been evaluated at the second stage. It appeared to have a high specificity of 83.3%, a sensitivity of 95.8%, and a diagnostic accuracy of 93.3%. Conclusion. The developed model for predicting CHF progression within 48 weeks after STEMI has a high diagnostic efficiency and can be used in early stages of myocardial infarction to stratify the risk of patients.

show abstract

Multifactor predictive model in patients with myocardial infarction based on modern biomarkers

Cited by 6 publications

References 14 publications

Prognostic Value of Pentraxin-3 Change After Primary Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction

Prognostic Value of Pentraxin-3 Change After Primary Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction

Diagnostic value and prognostic significance of CTRP9 combined with pentraxin‑3 in acute coronary syndrome

A Multivariate Model to Predict Chronic Heart Failure after Acute ST-Segment Elevation Myocardial Infarction: Preliminary Study

Contact Info

Product

Resources

About